Addition of chemo-immunotherapy to standard induction chemotherapy for high-risk neuroblastoma. Read more about Addition of chemo-immunotherapy to standard induction chemotherapy for high-risk neuroblastoma.
Clinical and radiographic characteristics of patients with metastatic breast cancer and pseudocirrhosis: A single-center retrospective cohort study. Read more about Clinical and radiographic characteristics of patients with metastatic breast cancer and pseudocirrhosis: A single-center retrospective cohort study.
Evaluating predictors of food insecurity among patients with cancer in the safety-net setting. Read more about Evaluating predictors of food insecurity among patients with cancer in the safety-net setting.
Implementation of a “genetic testing station” in a safety net hospital to optimize access and increase equity. Read more about Implementation of a “genetic testing station” in a safety net hospital to optimize access and increase equity.
Imaging of solid tumors using 68Ga-FAP-2286. Read more about Imaging of solid tumors using 68Ga-FAP-2286.
Serial stereotactic body radiation therapy for oligometastatic prostate cancer (PCa) detected by positron emission tomography (PET) imaging. Read more about Serial stereotactic body radiation therapy for oligometastatic prostate cancer (PCa) detected by positron emission tomography (PET) imaging.
Evaluating therapeutic bladder cancer trial disparities in race/ethnicity. Read more about Evaluating therapeutic bladder cancer trial disparities in race/ethnicity.
Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Read more about Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). Read more about Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC). Read more about Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC).
